An open-label study to investigate the excretion and metabolic disposition of a single, oral dose of [14C]-SB-751689 [ronacaleret] (a calcium-sen.sing receptor antagonist) in healthy male subjects and healthy postmenopausal female subjects

Trial Profile

An open-label study to investigate the excretion and metabolic disposition of a single, oral dose of [14C]-SB-751689 [ronacaleret] (a calcium-sen.sing receptor antagonist) in healthy male subjects and healthy postmenopausal female subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2009

At a glance

  • Drugs Ronacaleret (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jun 2008 Actual end date for this trial is now Jul 2007 as reported by ClinicalTrials.gov
    • 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 10 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top